Strides Pharma Science share news, announcements and annual reports
NSE: STARBSE: 532531Pharmaceuticals & BiotechnologySmall Cap
Strides Pharma Science Limited · Formerly Strides Shasun · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000 on NSE, Jun 2004 on BSE
Last close ₹1,068.80down ₹28.70 (2.62%)BSE ₹1,069.15
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,097.50.
30 Oct: open ₹1,050.00, high ₹1,076.90, low ₹972.00
52-week range of traded prices to 30 Oct 2026
₹768.65Low, 29 Jan 2026₹1,260.90High, 21 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹9,851 Cr580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 15.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.88
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.47%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 26,77,98551.0% delivered
Strides Pharma Science has 1,447 announcements on record, routine notices left out; 7 in the 30 days to 2 Nov 2026, the latest on 30 Oct 2026.
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Strides Pharma Science quarterly results
Oct29Thu
The board met on 29 Oct 2026 to consider financial results
Notice filed 23 Oct 2026
To consider and approve the financial results for the period ended September 30, 2026
Strides Pharma Science annual reports, presentations and earnings calls
The company's own documents, latest first.Strides Pharma Science financials, year by year
Annual reports18
- Annual report, year to Mar 202621 Jul 2026
- Annual report, year to Mar 202511 Jul 2025
- Annual report, year to Mar 20242 Sep 2024
- Annual report, year to Mar 20234 Aug 2023, a zip file
- Annual report, year to Mar 20223 Sep 2022, a zip file
13 earlier reports
- Annual report, year to Mar 202111 Aug 2021, a zip file
- Annual report, year to Mar 202029 Jul 2020, a zip file
- Annual report, year to Mar 20195 Jul 2019, a zip file
- Annual report, year to Mar 201825 Sep 2018, a zip file
- Annual report, year to Mar 201715 Sep 2017, a zip file
- Annual report, year to Mar 201610 Aug 2016, a zip file
- Annual report, year to Mar 201531 Jul 2015, a zip file
- Annual report, year to Mar 20143 Sep 2014, a zip file
- Annual report, year to Dec 20128 Jun 2013, a zip file
- Annual report, year to Dec 201124 Jul 2012, a zip file
- Annual report, year to Dec 201024 Jul 2012, a zip file
- Annual report, year to Dec 200913 Apr 2011, a zip file
- Annual report, year to Mar 20088 Oct 2009, a zip file
Investor presentations8
- Earnings Presentation for the quarter and half year ended September 30, 202629 Oct 2026
- Investor Presentation for Earnings call on Q1 FY 202731 Jul 2026
- Outcome of Board Meeting held on May 18, 2026 - Earnings Presentation for the quarter and year ended March 31, 202618 May 2026
- Earnings Presentation for Q3 & 9 Months FY2630 Jan 2026
- Investor Presentation29 Jul 2024
3 earlier presentations
- Investor Presentation2 Feb 2024
- Investor presentation issued by the Company on the merger of Shasun Pharmaceuticals in Strides Arcolab.30 Sep 2014, a zip file
- Analyst Presentation titled "Sale of generic pharmaceutical operations in Australia and Southeast Asia for AU$ 375 million".24 Jan 2012, a zip file
Earnings calls41
- Link of Recording30 Oct 2026
- Transcript of Earnings Call pertaining to Unaudited Financial Results of the Company for the quarter ended June 30, 2026.3 Aug 2026
- Second document filed with: Audio Recording of Earnings Call dated July 31, 2026, pertaining to unaudited financial results for Q1 FY2731 Jul 2026
- Audio Recording of Earnings Call dated July 31, 2026, pertaining to unaudited financial results for Q1 FY2731 Jul 2026
- Transcript of Earnings Call pertaining to audited Financial Results of the Company for the quarter and financial year ended March 31, 202621 May 2026
36 earlier call documents
- Link of Earnings Call Recording18 May 2026
- Transcript of Earnings call related to unaudited financial results of the Company for Quarter and Nine months ended December 31, 2025.3 Feb 2026
- Link of Recording30 Jan 2026
- Transcript of earnings call held on October 31, 20255 Nov 2025
- Link of Recording31 Oct 2025
- Link of Recording of Earnings Call31 Oct 2025
- Transcript4 Aug 2025
- Link of Recording29 Jul 2025
- Transcript27 May 2025
- Audio Recording of Earnings Call pertaining to the Audited Financial Results for the quarter and financial year ended March 31, 202522 May 2025
- Transcript4 Feb 2025
- Link of Recording30 Jan 2025
- Transcript29 Oct 2024
- Link of Recording24 Oct 2024
- Transcript5 Aug 2024
- Link of Recording29 Jul 2024
- Transcript27 May 2024
- Link of Recording22 May 2024
- Earnings Call Transcript5 Feb 2024
- Link of Recording30 Jan 2024
- Transcript3 Nov 2023
- Link of Recording30 Oct 2023
- Transcript3 Oct 2023
- Link of Recording25 Sep 2023
- Transcript7 Aug 2023
- Link of Recording2 Aug 2023
- Transcript1 Jun 2023
- Link of Recording25 May 2023
- Transcript1 Feb 2023
- Link of Recording25 Jan 2023
- Transcript of Analysts/Institutional Investor Meet/Con. Call22 Nov 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call16 Nov 2022
- Transcript of Analysts/Institutional Investor Meet/Con. Call4 Aug 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call30 Jul 2022
- Transcript of Analysts/Institutional Investor Meet/Con. Call1 Jun 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call pertaining to the Financial Results for the Quarter and Financial Year Ended March 31, 202225 May 2022
Strides Pharma Science merger and demerger filings
Filings about a merger, demerger or scheme of arrangement, latest first.
Filings17
- De-merger of Identified Business of Arco Lab Private Limited ( Arco Lab ), a wholly owned subsidiary of the Company15 May 2025
- Cost of Acquisition of Equity Shares pursuant to Demerger.11 Dec 2024
- Allotment of Equity Shares by Onesource (Resulting Company).11 Dec 2024
- Strides is pleased to announce that the Hon'ble National Company Law Tribunal (NCLT), Mumbai Bench, has pronounced Order on November 14, 2024 (which was uploaded on NCLT website on November 19, 2024) sanctioning the Scheme of Arrangement for the creation of OneSource, India s first specialty pharma CDMO.19 Nov 2024
- Scheme of Arrangement25 Sep 2023
12 earlier filings
- Scheme of Arrangement2 Aug 2023
- Scheme of Arrangement10 Feb 2022
- Update on Amalgamation/Merger12 Nov 2020
- Scheme of Arrangement29 Oct 2020
- Amalgamation/Merger of its wholly owned subsidiaries into itself19 Jun 2020
- Scheme of Arrangement30 Jan 2020
- Scheme of Arrangement29 Jul 2019
- Apportionment of the Cost of Acquisition of equity shares20 Apr 2018, a zip file
- Composite Scheme of Arrangement between Strides Shasun Limited, SeQuent Scientific Limited and Solara Active Pharma Sciences Limited and their respective Shareholders and Creditors .23 Mar 2018, a zip file
- Approval of Composite Scheme of Arrangement between Strides Shasun Limited (Company) and SeQuent Scientific Limited and SSL Pharma Sciences Limited and their respective shareholders and creditors.20 Mar 2017, a zip file
- Vide letter dated September 16, 2015 that "In furtherance to our intimation to the Stock Exchanges vide our letter dated August 28, 2015 informing about the oral order approving the Scheme of Amalgamation from Hon'ble High Court of Bombay, we wish to inform you that the Company has now received an authenticated copy of the Court Order. The Scheme of Amalgamation shall be effective post receipt of approval of Foreign Investment Promotion Board and on filing of a copy of the Order with Registrar of Companies, Bombay".16 Sep 2015, a zip file
- Hon'ble High Court of Bombay has on August 28, 2015 orally pronounced an Order, approving the Scheme of Amalgamation involving merger of Shasun Pharmaceuticals Limited with the Company, Strides Arcolab Limited. The certified true copy of the said Order is awaited.The Scheme of Amalgamation shall be effective post receipt of approval of Foreign Investment Promotion Board and on filing of a copy of the Order with Registrar of Companies, Bombay.28 Aug 2015, a zip file
Strides Pharma Science share news and announcements
Newest first. Page 1 of 29.
Oct 2026
29 Oct · Disclosure
29 Oct · Results
23 Oct · Analysts
23 Oct · Board meeting
Sep 2026
23 Sep · General Updates
11 Sep · General Updates
Aug 2026
14 Aug · Meeting
Jul 2026
31 Jul · Results
21 Jul · General Updates
21 Jul · Meeting
20 Jul · Corporate action
3 Jul · Sale or disposal
Jun 2026
27 Jun · Sale or disposal
8 Jun · Analysts
May 2026
28 May · Analysts
28 May · Analysts
28 May · Analysts
28 May · Analysts
28 May · Analysts
20 May · General Updates
20 May · Board meeting
18 May · Management
18 May · Management
18 May · Board meeting
18 May · Board meeting
18 May · Results
18 May · General Updates
Mar 2026
17 Mar · Arrangements for strategic, technical, manufacturing, or marketing tie up
Feb 2026
How the price met the news
The latest 30. The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 30 Oct 2026Resultsdown 2.62%−2.4 pts vs Nifty 500market median −0.7% · volume 9.8× usual · delivery +1.2 pts against usual · The announcement
- 31 Jul 2026Resultsdown 4.46%−4.9 pts vs Nifty 500market median −0.7% · five sessions −7.0% (−8.7 pts vs Nifty 500) · volume 11.5× usual · delivery −25.1 pts against usual · The announcement
- 19 May 2026Board or managers changedup 0.19%−0.1 pts vs Nifty 500market median 0.0% · five sessions +3.2% (+1.1 pts vs Nifty 500) · volume 3.5× usual · delivery −3.5 pts against usual · The announcement
- 18 May 2026Resultsdown 0.20%+0.1 pts vs Nifty 500market median −0.7% · five sessions 0.0% (−0.6 pts vs Nifty 500) · volume 4.9× usual · delivery −25.2 pts against usual · The announcement
- 30 Jan 2026Resultsup 8.31%+8.5 pts vs Nifty 500market median −0.7% · five sessions +7.0% (+5.3 pts vs Nifty 500) · volume 13.1× usual · delivery −30.6 pts against usual · The announcement
- 3 Dec 2025Board or managers changeddown 0.56%−0.1 pts vs Nifty 500market median 0.0% · five sessions −0.9% (+0.4 pts vs Nifty 500) · volume 0.6× usual · delivery +0.4 pts against usual · The announcement
- 31 Oct 2025Resultsup 9.66%+10.2 pts vs Nifty 500market median −0.7% · five sessions +11.2% (+12.6 pts vs Nifty 500) · volume 30.6× usual · delivery −35.9 pts against usual · The announcement
- 29 Jul 2025Board or managers changedup 3.49%+2.8 pts vs Nifty 500market median 0.0% · five sessions −9.1% (−9.2 pts vs Nifty 500) · volume 4.3× usual · delivery −12.7 pts against usual · The announcement
- 29 Jul 2025Resultsup 3.49%+2.8 pts vs Nifty 500market median −0.7% · five sessions −9.1% (−9.2 pts vs Nifty 500) · volume 4.3× usual · delivery −12.7 pts against usual · The announcement
- 23 Jul 2025Board or managers changedup 4.68%+4.2 pts vs Nifty 500market median 0.0% · five sessions +8.7% (+10.1 pts vs Nifty 500) · volume 1.1× usual · delivery −2.9 pts against usual · The announcement
20 earlier announcements
- 22 May 2025Resultsup 5.00%+5.6 pts vs Nifty 500market median −0.7% · five sessions +2.8% (+2.6 pts vs Nifty 500) · volume 7.5× usual · delivery −17.9 pts against usual · The announcement
- 30 Jan 2025Resultsup 8.17%+7.9 pts vs Nifty 500market median −0.7% · five sessions +13.1% (+10.8 pts vs Nifty 500) · volume 6.1× usual · delivery −39.6 pts against usual · The announcement
- 24 Oct 2024Resultsdown 1.61%−1.4 pts vs Nifty 500market median −0.7% · five sessions −2.2% (−1.8 pts vs Nifty 500) · volume 1.9× usual · delivery −22.4 pts against usual · The announcement
- 29 Aug 2024Board or managers changedup 0.58%+0.5 pts vs Nifty 500market median 0.0% · five sessions +4.4% (+3.9 pts vs Nifty 500) · volume 0.3× usual · delivery −3.1 pts against usual · The announcement
- 22 May 2024Dividendup 6.32%+6.1 pts vs Nifty 500market median 0.0% · five sessions −3.7% (−4.6 pts vs Nifty 500) · volume 9.0× usual · delivery −29.3 pts against usual · The announcement
- 22 May 2024Resultsup 6.32%+6.1 pts vs Nifty 500market median −0.7% · five sessions −3.7% (−4.6 pts vs Nifty 500) · volume 9.0× usual · delivery −29.3 pts against usual · The announcement
- 22 May 2024Board or managers changedup 6.32%+6.1 pts vs Nifty 500market median 0.0% · five sessions −3.7% (−4.6 pts vs Nifty 500) · volume 9.0× usual · delivery −29.3 pts against usual · The announcement
- 30 Oct 2023Board or managers changeddown 1.89%−2.2 pts vs Nifty 500market median 0.0% · five sessions −5.0% (−6.4 pts vs Nifty 500) · volume 3.0× usual · delivery −27.3 pts against usual · The announcement
- 4 Sep 2023Board or managers changedup 1.37%+0.7 pts vs Nifty 500market median 0.0% · five sessions +9.7% (+7.3 pts vs Nifty 500) · volume 1.6× usual · delivery −0.8 pts against usual · The announcement
- 2 Aug 2023Resultsdown 7.10%−6.0 pts vs Nifty 500market median −0.7% · five sessions −8.2% (−7.6 pts vs Nifty 500) · volume 3.8× usual · delivery −10.4 pts against usual · The announcement
- 25 May 2023Dividenddown 3.73%−4.0 pts vs Nifty 500market median 0.0% · five sessions −4.8% (−6.5 pts vs Nifty 500) · volume 8.1× usual · delivery −22.7 pts against usual · The announcement
- 14 Nov 2022Resultsup 8.13%+8.1 pts vs Nifty 500market median −0.7% · five sessions +6.3% (+7.0 pts vs Nifty 500) · volume 4.0× usual · delivery −16.5 pts against usual · The announcement
- 14 Nov 2022Board or managers changedup 8.13%+8.1 pts vs Nifty 500market median 0.0% · five sessions +6.3% (+7.0 pts vs Nifty 500) · volume 4.0× usual · delivery −16.5 pts against usual · The announcement
- 29 Jul 2022Resultsdown 0.90%−2.3 pts vs Nifty 500market median −0.7% · five sessions +5.0% (+2.1 pts vs Nifty 500) · volume 2.4× usual · delivery −11.4 pts against usual · The announcement
- 30 Mar 2022Board or managers changedup 1.02%+0.1 pts vs Nifty 500market median 0.0% · five sessions +3.9% (−0.4 pts vs Nifty 500) · volume 0.6× usual · delivery −4.6 pts against usual · The announcement
- 27 May 2021Dividenddown 0.63%−1.0 pts vs Nifty 500market median 0.0% · five sessions −6.7% (−8.6 pts vs Nifty 500) · volume 3.4× usual · delivery −14.4 pts against usual · The announcement
- 22 Jan 2021Credit ratingdown 3.60%−2.3 pts vs Nifty 500market median 0.0% · five sessions −7.4% (−1.4 pts vs Nifty 500) · volume 0.4× usual · delivery +5.3 pts against usual · The announcement
- 16 Jul 2020Dividenddown 0.90%−1.8 pts vs Nifty 500market median 0.0% · five sessions −2.8% (−6.9 pts vs Nifty 500) · volume 0.3× usual · delivery −9.7 pts against usual · The announcement
- 21 May 2020Dividendup 0.17%−0.4 pts vs Nifty 500market median 0.0% · five sessions −6.0% (−10.1 pts vs Nifty 500) · volume 2.5× usual · delivery −8.6 pts against usual · The announcement
- 30 Jul 2019Dividendup 5.22%+6.4 pts vs Nifty 500market median 0.0% · five sessions +14.0% (+17.0 pts vs Nifty 500) · volume 10.2× usual · delivery −10.2 pts against usual · The announcement
Strides Pharma Science results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.
Figures filed again
Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.
| Line | Period | Accounts | First filed | Filed again | Change. The value filed again less the value first filed, as a per cent of the first. | First filed on | Filed again on |
|---|---|---|---|---|---|---|---|
| Tax | Quarter to Jun 2018 | Consolidated | −4.27 | −5.87 | −37.5% | 8 Aug 2018 | 31 Oct 2018 |
| Net profit | Quarter to Jun 2018 | Consolidated | −4.16 | −2.56 | +38.5% | 8 Aug 2018 | 31 Oct 2018 |
| Deferred tax | Quarter to Jun 2018 | Consolidated | −6.41 | −8.01 | −25.0% | 8 Aug 2018 | 31 Oct 2018 |
| Net profit from continuing businesses | Quarter to Jun 2018 | Consolidated | 3.76 | 5.36 | +42.6% | 8 Aug 2018 | 31 Oct 2018 |
| Total comprehensive income | Quarter to Jun 2018 | Consolidated | −26.43 | −24.83 | +6.1% | 8 Aug 2018 | 31 Oct 2018 |
| Net profit belonging to the company's shareholders | Quarter to Jun 2018 | Consolidated | −5.91 | −4.31 | +27.1% | 8 Aug 2018 | 31 Oct 2018 |
| Total comprehensive income belonging to the company's shareholders | Quarter to Jun 2018 | Consolidated | −29.49 | −27.89 | +5.4% | 8 Aug 2018 | 31 Oct 2018 |
| Other comprehensive income that stays out of profit | Quarter to Jun 2018 | Consolidated | 0.02 | −0.03 | −250.0% | 8 Aug 2018 | 31 Oct 2018 |
| Other comprehensive income that may later move into profit | Quarter to Jun 2018 | Consolidated | −22.29 | −30.22 | −35.6% | 8 Aug 2018 | 31 Oct 2018 |